Csontvelo-transzplantáció az imatinib korszakban

Research output: Article

2 Citations (Scopus)

Abstract

Imatinib has profoundly changed our clinical practice in the treatment of CML. However, many questions remain to be answered including the role of haematopoietic stem cell transplantation. The main dilemma is that while there are no convincing data to support the hypothesis that imatinib is curative in CML, there are very good remissions without important side effects. On the other hand there is strong evidence with long follow-up that CML can be cured by stem cell transplantation, although there is a high risk of transplant-related complications. This review will focus on the current international practice, on the results of imatinib treatment as well as on that of stem cell transplantation. The author will attempt to provide a framework for the decision-making process in the treatment of CML in which the contribution of the patient's preferences should be crucial.

Original languageHungarian
Pages (from-to)900-904
Number of pages5
JournalOrvosi Hetilap
Volume146
Issue number18 SUPPL.1
Publication statusPublished - 2005

Fingerprint

Stem Cell Transplantation
Patient Preference
Hematopoietic Stem Cell Transplantation
Decision Making
Therapeutics
Transplants
Imatinib Mesylate

Keywords

  • CML
  • Imatinib
  • Stem cell transplantation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Csontvelo-transzplantáció az imatinib korszakban. / Masszi, T.

In: Orvosi Hetilap, Vol. 146, No. 18 SUPPL.1, 2005, p. 900-904.

Research output: Article

Masszi, T 2005, 'Csontvelo-transzplantáció az imatinib korszakban', Orvosi Hetilap, vol. 146, no. 18 SUPPL.1, pp. 900-904.
Masszi, T. / Csontvelo-transzplantáció az imatinib korszakban. In: Orvosi Hetilap. 2005 ; Vol. 146, No. 18 SUPPL.1. pp. 900-904.
@article{d171e563748e448db3993c1f40603d03,
title = "Csontvelo-transzplant{\'a}ci{\'o} az imatinib korszakban",
abstract = "Imatinib has profoundly changed our clinical practice in the treatment of CML. However, many questions remain to be answered including the role of haematopoietic stem cell transplantation. The main dilemma is that while there are no convincing data to support the hypothesis that imatinib is curative in CML, there are very good remissions without important side effects. On the other hand there is strong evidence with long follow-up that CML can be cured by stem cell transplantation, although there is a high risk of transplant-related complications. This review will focus on the current international practice, on the results of imatinib treatment as well as on that of stem cell transplantation. The author will attempt to provide a framework for the decision-making process in the treatment of CML in which the contribution of the patient's preferences should be crucial.",
keywords = "CML, Imatinib, Stem cell transplantation",
author = "T. Masszi",
year = "2005",
language = "Hungarian",
volume = "146",
pages = "900--904",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "18 SUPPL.1",

}

TY - JOUR

T1 - Csontvelo-transzplantáció az imatinib korszakban

AU - Masszi, T.

PY - 2005

Y1 - 2005

N2 - Imatinib has profoundly changed our clinical practice in the treatment of CML. However, many questions remain to be answered including the role of haematopoietic stem cell transplantation. The main dilemma is that while there are no convincing data to support the hypothesis that imatinib is curative in CML, there are very good remissions without important side effects. On the other hand there is strong evidence with long follow-up that CML can be cured by stem cell transplantation, although there is a high risk of transplant-related complications. This review will focus on the current international practice, on the results of imatinib treatment as well as on that of stem cell transplantation. The author will attempt to provide a framework for the decision-making process in the treatment of CML in which the contribution of the patient's preferences should be crucial.

AB - Imatinib has profoundly changed our clinical practice in the treatment of CML. However, many questions remain to be answered including the role of haematopoietic stem cell transplantation. The main dilemma is that while there are no convincing data to support the hypothesis that imatinib is curative in CML, there are very good remissions without important side effects. On the other hand there is strong evidence with long follow-up that CML can be cured by stem cell transplantation, although there is a high risk of transplant-related complications. This review will focus on the current international practice, on the results of imatinib treatment as well as on that of stem cell transplantation. The author will attempt to provide a framework for the decision-making process in the treatment of CML in which the contribution of the patient's preferences should be crucial.

KW - CML

KW - Imatinib

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=23844475886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844475886&partnerID=8YFLogxK

M3 - Article

C2 - 15921302

AN - SCOPUS:23844475886

VL - 146

SP - 900

EP - 904

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 18 SUPPL.1

ER -